يعرض 1,061 - 1,080 نتائج من 17,850 نتيجة بحث عن '(( significant decrease decrease ) OR ( significance a decrease ))~', وقت الاستعلام: 0.29s تنقيح النتائج
  1. 1061

    Why Only the 2,6-Bis(o-Carborano)Pyridine-Stabilized Phosphenium Cation Has Succeeded in Splitting H<sub>2</sub>?: Key Design Insights for Next-Gen Phosphenium Pincer Catalysts حسب Mohmmad Faizan (14122382)

    منشور في 2025
    "…These findings underscore the significant influence of ligand architecture on the reactivity of <b>1</b><sup><b>+</b></sup> toward H<sub>2</sub> activation. …"
  2. 1062

    Why Only the 2,6-Bis(o-Carborano)Pyridine-Stabilized Phosphenium Cation Has Succeeded in Splitting H<sub>2</sub>?: Key Design Insights for Next-Gen Phosphenium Pincer Catalysts حسب Mohmmad Faizan (14122382)

    منشور في 2025
    "…These findings underscore the significant influence of ligand architecture on the reactivity of <b>1</b><sup><b>+</b></sup> toward H<sub>2</sub> activation. …"
  3. 1063

    Why Only the 2,6-Bis(o-Carborano)Pyridine-Stabilized Phosphenium Cation Has Succeeded in Splitting H<sub>2</sub>?: Key Design Insights for Next-Gen Phosphenium Pincer Catalysts حسب Mohmmad Faizan (14122382)

    منشور في 2025
    "…These findings underscore the significant influence of ligand architecture on the reactivity of <b>1</b><sup><b>+</b></sup> toward H<sub>2</sub> activation. …"
  4. 1064

    Why Only the 2,6-Bis(o-Carborano)Pyridine-Stabilized Phosphenium Cation Has Succeeded in Splitting H<sub>2</sub>?: Key Design Insights for Next-Gen Phosphenium Pincer Catalysts حسب Mohmmad Faizan (14122382)

    منشور في 2025
    "…These findings underscore the significant influence of ligand architecture on the reactivity of <b>1</b><sup><b>+</b></sup> toward H<sub>2</sub> activation. …"
  5. 1065

    Annual treatment frequencies in all eyes. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…"
  6. 1066
  7. 1067
  8. 1068

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…CRT in the recurrence group significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …"
  9. 1069

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…Regarding the mean number of treatments in the recurrence group, anti-VEGF, STTA, MA-PC, PPV, and total treatment counts in the year before surgery were 3.0 ± 1.4, 0.1 ± 0.3, 0.8 ± 1.0, 0.1 ± 0.3, and 4.0 ± 2.1, respectively. These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …"
  10. 1070
  11. 1071
  12. 1072
  13. 1073
  14. 1074
  15. 1075
  16. 1076
  17. 1077
  18. 1078
  19. 1079
  20. 1080